Dutch Medicine Access Delay Impact on Patient Care in the Netherlands

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory added-value assessments and price negotiations that only begin after European Medicines Agency approval.

Oncology Drugs Stuck at the Border

The Dutch medicine access delay, as reported by AD (linked below), is especially painful in oncology. Two advanced multiple myeloma therapies developed in close partnership with Dutch academic hospitals are already available to German patients. Both treatments extend stable disease periods, reduce side effects, and meaningfully improve quality of life, yet remain out of reach for people in the Netherlands.

655 Days Trapped in the Sluice

On average, medicines spend 655 days — nearly two years — in the Netherlands’ “sluice” mechanism before reimbursement is agreed. Germany, by contrast, grants immediate market access after EMA approval and completes price talks within six statutory months. The growing frequency of failed negotiations in the Dutch system is widening this gap.

When Collaboration Doesn’t Reach Dutch Patients

The situation becomes even more striking when the therapies in question were partly created with Dutch expertise. Despite local scientific contributions, patients must wait while neighboring countries move forward. Long-term differences in survival and disease progression linked to this Dutch medicine access delay will not be measurable for years.

Time to Rebuild the Reimbursement Model

Current Dutch processes prioritize cost control but deliver access timelines that far exceed Germany’s results, often without achieving meaningfully lower prices. As Dutch patients are increasingly advised to seek treatment abroad, policymakers face growing pressure to modernize value assessment methods so that innovation reaches patients while fiscal responsibility is maintained.